UPDATE: See our article here highlighting changes relative to the June 2020 draft Guidelines.
This morning, the PMPRB released the final Guidelines operationalizing the amended Patented Medicines Regulations (Amended...more
The first decision considering the scope and meaning of the provisions in the Patent Act relating to Certificates of Supplementary Protection (CSPs) has now been released. Justice Barnes of the Federal Court in...more
5/14/2020
/ Canada ,
Certificates of Supplementary Protection (CSPs) ,
CETA ,
EU ,
GlaxoSmithKline ,
Health Canada ,
Patent Act ,
Patent Litigation ,
Patented Medicines ,
Patents ,
Vaccinations
The following are highlights of developments in Canadian life sciences intellectual property and regulatory law in 2016, updating our 2016 mid-year highlights.
1. Substantive patent law developments -
Utility and...more
1/11/2017
/ Administrative Proceedings ,
Anti-Competitive ,
Apotex ,
Arbitration ,
AstraZeneca ,
Bayer ,
Biologics ,
Biosimilars ,
CADTH ,
Calculation of Damages ,
CETA ,
Competition Authorities ,
Constitutional Challenges ,
Data Protection ,
Double Patent ,
Eli Lilly ,
Generic Drugs ,
Health Canada ,
Leave to Appeal ,
Life Sciences ,
NAFTA ,
New Guidance ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Terms ,
Patented Medicine Prices Review Board (PMPRB) ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Supreme Court of Canada ,
Teva Pharmaceuticals ,
Trans-Pacific Partnership ,
Unjust Enrichment ,
Utility Patents
On October 31, 2016, the day following the signing of CETA, the Canadian Minister of International Trade, the Honourable Chrystia Freeland, tabled Bill C-30, An Act to implement the Comprehensive Economic and Trade Agreement...more
11/2/2016
/ Appeals ,
Canada ,
Canadian Patent Office ,
CETA ,
EU ,
Exports ,
Foreign Patent Applications ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Pharmaceutical Patents ,
Proposed Legislation ,
Supplementary Protection Certificate ,
Trade Agreements